Survival analysis of preoperative involved-field irradiation with concurrent chemotherapy for patients with Siewert′s type Ⅱ and Ⅲ adenocarcinoma of esophagogastric junction
Huang Xin, Wang Jun, Zhao Qun, Cheng Yunjie, Tian Yuan, Wang Yi, Cao Feng, Jing Shaowu, Jiao Wenpeng, Wu Yajing
Department of Radiation Oncology (Wang J,Cheng YJ,Wang Y,Cao F,Jing SW,Jiao WP,Wu YJ),Third Department of Surgery (Zhao Q,Tian Y),Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China First Department of Oncology,Hebei General Hospital,Shijiazhuang 050051,China (Huang X)
Abstract： Objective To analyze the clinical efficacy,toxicity and survival prognosis of patients diagnosed with Siewert type Ⅱ and Ⅲ locally advanced adenocarcinoma of esophagogastric junction (AEG) undergoing preoperative involved-field irradiation with concurrent chemotherapy. Methods A total of 45 cases were recruited in this prospective clinical trial. Prior to surgery,patients received 2 cycles of chemotherapy with XELOX and concurrent radiotherapy (a total of 45 Gy in 25 fractions,5 times weekly).After 6-8 weeks,they underwent surgical resection. After the surgery,patients received 6 cycles of adjuvant chemotherapy. The completion of preoperative neoadjuvant chemoradiotherapy,postoperative pathological status,TNM down-staging effect and adverse reactions were observed. Kaplan-Meier method was applied to estimate survival analysis. Results All 45 patients completed preoperative neoadjuvant chemoradiotherapy. Among them,39 patients completed 2 cycles of chemotherapy,and 6 patients completed 1 cycle of chemotherapy. The median time of surgical interval was 6 weeks. The R0 resection rate was 96%.The pathological complete response (pCR) rate was 22%. The TNM down-staging rate was 69%.The incidence of acute radiation-induced esophagitis or gastritis was 44% and the incidence of radiation-induced pneumonitis was 7%. The incidence of grade 1-3 leukocytopenia,thrombocytopenia and neutropenia was 78%,47% and 44%,respectively. In terms of gastrointestinal reactions,the incidence of nausea,vomiting and loss of appetite was 62%,24% and 71%,respectively. No hematologic or nonhematologic adverse effects was observed at grade 4 or 5.The median follow-up time was 30 months.11 patients died of cancer,1 patient was treatment-related death in the perioperative period and 1 patient died of pneumonia.The 1-,2-and 3-year progression-free survival (PFS) rates were 90%,70% and 67%,respectively.The 1-,2-and 3-year overall survival rates were 95%,80% and 75%,respectively. The 1-,2-and 3-year local control rates were 95%,84% and 84%,respectively. The 1-,2-and 3-year distant metastasis rates were 7%,25% and 25%,respectively. Conclusions Preoperative involved-field irradiation with concurrent chemotherapy yields relatively high clinical efficacy and is well tolerated by patients with Siewert type Ⅱ and Ⅲ locally advanced AEG.Patients are recommended to receive 4 cycles of adjuvant chemotherapy following neoadjuvant chemoradiotherapy and surgery.
Huang Xin,Wang Jun,Zhao Qun et al. Survival analysis of preoperative involved-field irradiation with concurrent chemotherapy for patients with Siewert′s type Ⅱ and Ⅲ adenocarcinoma of esophagogastric junction[J]. Chinese Journal of Radiation Oncology, 2018, 27(7): 649-655.
[1] Piso P,Werner U,Lang H,et al. Proximal versus distal gastric carcinoma-what are the differences?[J].Ann Surg Oncol,2000,7(7):520-525.DOI:10.1007/s10434-000-0520-0. [2] Ferlay J,Soerjomataram I,Ervik M,et al. GLOBOCAN 2012:estimated cancer incidence,mortality and prevalence worldwide in 2012[R].Lyon,France:World Health Organization,2014:8-10. [3] Siegel RL,Miller KD,Jemal A.Cancer statistics,2016[J].Ca Cancer J Clin,2016,66(1):7-30.DOI:10.3322/caac.21332. [4] 陈志峰,侯浚,贺宇彤.食管胃交界腺癌——食管癌高发区面临的新课题[J].肿瘤防治研究,2007,34(11):883-885.DOI:10.3971/j.issn.1000-8578.2007.11.021. Chen ZF,Hou J,He YT.New theme faced with adenocarcinoma of oesophagogastric junction esophageal cancer in high-risk area[J].Cancer Res Prev Treat,2007,34(11):883-885.DOI:10.3971/j.issn.1000-8578.2007.11.021. [5] Gaast AV,Van Hagen P,Hulshof M,et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer:results from a multicenter randomized phase Ⅲ study[J].J Clin Oncol,2010,28(15):4004.DOI:10.1200/jco.2010.28.15_suppl.4004. [6] Van Hagen P,Hulshof MCCM,Van Lanschot JJB,et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J].N Engl J Med,2012,366(22):2074-2084.DOI:10.1056/NEJMoa1112088. [7] Shapiro J,Van Lanschot J J,Hulshof M C,et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS):long-term results of a randomised controlled trial[J].Lancet Oncol,2015,16(9):1090-1098.DOI:10.1016/S1470-2045(15)00040-6. [8] Stahl M,Walz MK,Stuschke M,et al. Phase Ⅲ comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction[J].J Clin Oncol,2009,27(6):851-856.DOI:10.1200/JCO.2008.17.0506. [9] Walsh TN,Noonan N,Hollywood D,et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma[J].N Engl J Med,1996,335(7):462-467.DOI:10.1056/NEJM199608153350702. [10] Urba SG,Orringer MB,Turrisi A,et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma[J].J Clin Oncol,2001,19(2):305-313.DOI:10.1200/JCO.2001.19.2.305. [11] Burmeister BH,Smithers BM,Gebski V,et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus:a randomised controlled phase Ⅲ trial[J].Lancet Oncol,2005,6(9):659-668.DOI:10.1016/S1470-2045(05)70288-6. [12] Tepper J,Krasna MJ,Niedzwiecki D,et al. Phase Ⅲ trial of trimodality therapy with cisplatin,fluorouracil,radiotherapy,and surgery compared with surgery alone for esophageal cancer:CALGB 9781[J].J Clin Oncol,2008,26(7):1086-1092.DOI:10.1200/JCO.2007.12.9593. [13] 王军,赵群,黄欣,等.Siewert Ⅱ、Ⅲ型食管胃结合部腺癌术前受累野照射同期化疗可行性分析[J].中华放射肿瘤学杂志,2017,26(11):1269-1275.DOI:10.3760/cma.j.issn.1004-4221.2017.11.006. Wang J,Zhao Q,Huang X,et al. Feasibility of intensity-modulated radiation therapy with concurrent chemotherapy in patients with Siewert type Ⅱ and Ⅲ adenocarcinoma of the esophagogastric junction before surgery[J].Chin J Radiat Oncol,2017,26(11):1269-1275.DOI:10.3760/cma.j.issn.1004-4221.2017.11.006. [14] National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 and v4.0(CTCAE).[2011-06-14].http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. [15] Enzinger PC,Mayer RJ.Esophageal cancer[J].N Engl J Med,2003,349(23):2241-2252.DOI:10.1056/NEJMra035010. [16] Reynolds JV,Preston SR,O′Neill B,et al. ICORG 10-14:neoadjuvant trial in adenocarcinoma of the oesophagus and oesophagogastric junction international study (Neo-AEGIS)[J].BMC Cancer,2017,17:401.DOI:10.1186/s12885-017-3386-2. [17] 王军,张辛,韩春,等.根据胸段食管癌淋巴结转移规律探讨术后预防性照射范围和适应证[J].中华放射肿瘤学杂志,2009,18(4):265-269.DOI:10.3760/cma.j.issn.1004-4221.2009.04.265. Wang J,Zhang X,Han C,et al. Pattern of lymph nade metastasis in determining the indication and target of post-operative prophylactic radiotherapy for thoracic esophageal carcinoma[J].Chin J Radiat Oncol,2009,18(4):265-269.DOI:10.3760/cma.j.issn.1004-4221.2009.04.265. [18] 王永岗,汪良骏,张德超,等.胸段食管鳞癌淋巴结转移特点及临床意义[J].中华肿瘤杂志,2000,22(3):241-243.DOI:10.3760/j.issn:0253-3766.2000.03.025. Wang YG,Wang LJ,Zhang DC,et al. Characteristics of lymph node metastasis of squamous cell carcinoma of thoracic esophagus and its clinical significance[J].Chin J Oncol,2000,22(3):241-243.DOI:10.3760/j.issn:0253-3766.2000.03.025. [19] 李进东,王文光,许金良,等.胸段食管癌淋巴结转移特点的研究[J].中华医学杂志,2006,86(45):3197-3200.DOI:10.3760/j.issn.0376-2491.2006.45.008. Li JD,Wang WG,Xu JL,et al. Characteristics of lymph node metastasis in thoracic esophageal carcinoma[J].Natl Med J China,2006,86(45):3197-3200.DOI:10.3760/j.issn.0376-2491.2006.45.008. [20] 武卫鹏,邓靖宇,梁寒,等.远端胃癌淋巴结转移规律及临床意义[J].中国肿瘤临床,2015,42(18):906-911.DOI:10.3969/j.issn.1000-8179.2015.18.183. Wu WP,Deng JY,Liang H,et al. Regularity of lymph node metastasis in distal gastric cancer and its clinical significance[J].Chin J Clin Oncol,2015,42(18):906-911.DOI:10.3969/j.issn.1000-8179.2015.18.183. [21] 曾长青,刘进生,郑羽,等.远端胃癌淋巴结转移规律与淋巴结清扫方式的探讨[J].中华胃肠外科杂志,2012,15(2):141-144.DOI:10.3760/cma.j.issn.1671-0274.2012.02.012. Zeng CQ,Liu JS,Zheng Y,et al. Pattern of lymph node metastasis and extent of lymphadenectomy for distal gastric cancer[J].Chin J Gastrointest Surg,2012,15(2):141-144.DOI:10.3760/cma.j.issn.1671-0274.2012.02.012. [22] Kleinberg LR,Eapen S,Hamilton S,et al.143:E1201:an Eastern Cooperative Oncology Group (ECOG) randomized phase Ⅱ trial to measure response rate and toxicity of preoperative combined modality Paclitaxel/Cisplatin/RT or Irinotecan/Cisplatin/RT in adenocarcinoma of the esophagus[J].Int J Radiat Oncol Biol Phys,2006,66(3 Suppl 1):S80.DOI:10.1016/j.ijrobp.2006.07.174. [23] Siewert JR,Stein HJ,Feith M.Adenocarcinoma of the esophago-gastric junction[J].Scand J Surg,2006,95(4):260-269.DOI:10.1177/145749690609500409. [24] Meier I,Merkel S,Papadopoulos T,et al. Adenocarcinoma of the esophagogastric junction:the pattern of metastatic lymph node dissemination as a rationale for elective lymphatic target volume definition[J].Int J Radiat Oncol Biol Phys,2008,70(5):1408-1417.DOI:10.1016/j.ijrobp.2007.08.053. [25] Ichikura T,Ogawa T,Kawabata T,et al. Is adenocarcinoma of the gastric cardia a distinct entity independent of subcardial carcinoma?[J].World J Surg,2003,27(3):334-338.DOI:10.1007/s00268-002-6776-8. [26] 王军,张彦军,刘青,等.食管胃结合部腺癌淋巴结转移规律对根治性放疗靶区勾画参考[J].中华放射肿瘤学杂志,2015,24(4):367-371.DOI:10.3760/cma.j.issn.1004-4221.2015.04.003. Wang J,Zhang YJ,Liu Q,et al. The patterns of lymph node metastasis in adenocarcinoma of esophagogastric junction:a reference for target volume delineation in radical radiotherapy[J].Chin J Radiat Oncol,2015,24(4):367-371.DOI:10.3760/cma.j.issn.1004-4221.2015.04.003. [27] Oppedijk V,Van Der Gaast A,Van Lanschot JJB,et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials[J].J Clin Oncol,2014,32(5):385-391.DOI:10.1200/JCO.2013.51.2186. [28] De Manzoni G,Pedrazzani C,Pasini F,et al. Pattern of recurrence after surgery in adenocarcinoma of the gastro-oesophageal junction[J].Eur J Surg Oncol,2003,29(6):506-510.DOI:10.1016/S0748-7983(03)00098-2. [29] Orditura M,Galizia G,Martino ND,et al. Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma— a pilot study[J].Curr Oncol,2014,21(3):125-133.DOI:10.3747/co.21.1570. [30] Wang JY,Milton DR,He LR,et al. Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas[J].J Thorac Oncol,2015,10(3):518-526.DOI:10.1097/JTO.0000000000000457. [31] Cunningham D,Allum WH,Stenning SP,et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J].N Engl J Med,2006,355(1):11-20.DOI:10.1056/NEJMoa055531. [32] Ychou M,Boige V,Pignon JP,et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma:an FNCLCC and FFCD multicenter phase Ⅲ trial[J].J Clin Oncol,2011,29(13):1715-1721.DOI:10.1200/JCO.2010.33.0597.
2018, Vol. 27 
